Notes to the Condensed Consolidated Interim Financial Statements of the Bayer Group as of June 30, 2017

Key Data by Segment

Key Data by Segment – Second Quarter 2017

 

 

Pharmaceuticals

 

Consumer Health

 

Crop Science

 

Animal Health

 

 

Q2 2016

Q2 2017

 

Q2 2016

Q2 2017

 

Q2 2016

Q2 2017

 

Q2 2016

Q2 2017

 

 

€ million

€ million

 

€ million

€ million

 

€ million

€ million

 

€ million

€ million

1

For definition see Annual Report 2016, Chapter “Alternative Performance Measures Used by the Bayer Group.”

Net sales (external)

 

4,104

4,304

 

1,553

1,542

 

2,518

2,163

 

426

450

Change1

 

+5.5%

+4.9%

 

−2.3%

−0.7%

 

−4.5%

−14.1%

 

−0.5%

+5.6%

Currency-adjusted change1

 

+8.4%

+4.4%

 

+4.0%

−2.2%

 

+0.7%

−15.8%

 

+4.2%

+4.0%

Intersegment sales

 

8

11

 

3

4

 

8

8

 

1

1

Net sales (total)

 

4,112

4,315

 

1,556

1,546

 

2,526

2,171

 

427

451

EBIT1

 

988

1,102

 

190

195

 

512

117

 

93

107

EBIT before special items1

 

999

1,222

 

222

210

 

542

212

 

93

107

EBITDA before special items1

 

1,352

1,481

 

328

314

 

663

317

 

100

116

Net cash provided by operating activities

 

310

528

 

241

297

 

1,088

1,170

 

48

97

Depreciation, amortization, impairment losses / loss reversals

 

354

372

 

107

112

 

121

116

 

7

9

Continuation of the previous table

 

 

Reconciliation

 

 

 

 

 

 

 

 

 

All Other Segments

 

Corporate Functions and Consolidation

 

Life Sciences

 

Covestro

 

Group

 

 

Q2 2016

Q2 2017

 

Q2 2016

Q2 2017

 

Q2 2016

Q2 2017

 

Q2 2016

Q2 2017

 

Q2 2016

Q2 2017

 

 

€ million

€ million

 

€ million

€ million

 

€ million

€ million

 

€ million

€ million

 

€ million

€ million

1

For definition see Annual Report 2016, Chapter “Alternative Performance Measures Used by the Bayer Group.”

Net sales (external)

 

256

252

 

1

3

 

8,858

8,714

 

2,975

3,479

 

11,833

12,193

Change1

 

−6.2%

−1.6%

 

 

+0.5%

−1.6%

 

−6.6%

+16.9%

 

−1.4%

+3.0%

Currency-adjusted change1

 

−5.5%

−0.8%

 

 

+4.7%

−2.7%

 

−3.9%

+15.8%

 

+2.4%

+2.0%

Intersegment sales

 

478

508

 

(516)

(551)

 

 

18

19

 

Net sales (total)

 

734

760

 

(515)

(548)

 

 

2,993

3,498

 

11,833

12,193

EBIT1

 

18

45

 

(30)

(103)

 

1,771

1,463

 

367

688

 

2,138

2,151

EBIT before special items1

 

40

58

 

(21)

(102)

 

1,875

1,707

 

367

649

 

2,242

2,356

EBITDA before special items1

 

88

118

 

(20)

(99)

 

2,511

2,247

 

543

809

 

3,054

3,056

Net cash provided by operating activities

 

170

(74)

 

(174)

(117)

 

1,683

1,901

 

309

415

 

1,992

2,316

Depreciation, amortization, impairment losses / loss reversals

 

48

60

 

1

3

 

638

672

 

176

160

 

814

832

Key Data by Segment – Half Year 2017

 

 

Pharmaceuticals

 

Consumer Health

 

Crop Science

 

Animal Health

 

 

H1 2016

H1 2017

 

H1 2016

H1 2017

 

H1 2016

H1 2017

 

H1 2016

H1 2017

 

 

€ million

€ million

 

€ million

€ million

 

€ million

€ million

 

€ million

€ million

1

For definition see Annual Report 2016, Chapter “Alternative Performance Measures Used by the Bayer Group.”

2

Full-time equivalents

Net sales (external)

 

7,993

8,567

 

3,073

3,143

 

5,454

5,283

 

834

890

Change1

 

+7.3%

+7.2%

 

−2.3%

+2.3%

 

−3.3%

−3.1%

 

+2.5%

+6.7%

Currency-adjusted change1

 

+10.2%

+5.8%

 

+3.1%

+0.2%

 

+1.0%

−5.4%

 

+6.4%

+4.4%

Intersegment sales

 

15

21

 

4

9

 

17

16

 

2

2

Net sales (total)

 

8,008

8,588

 

3,077

3,152

 

5,471

5,299

 

836

892

EBIT1

 

1,686

2,321

 

433

473

 

1,467

1,087

 

207

233

EBIT before special items1

 

1,928

2,477

 

497

497

 

1,500

1,219

 

208

233

EBITDA before special items1

 

2,613

2,983

 

711

706

 

1,752

1,432

 

222

251

Net cash provided by operating activities

 

1,044

1,501

 

438

562

 

422

491

 

28

66

Depreciation, amortization, impairment losses / loss reversals

 

917

652

 

228

218

 

252

237

 

14

18

Number of employees (as of June 30)2

 

40,197

37,999

 

13,085

11,898

 

22,839

20,969

 

3,859

3,621

Continuation of the previous table

 

 

Reconciliation

 

 

 

 

 

 

 

 

 

All Other Segments

 

Corporate Functions and Consolidation

 

Life Sciences

 

Covestro

 

Group

 

 

H1 2016

H1 2017

 

H1 2016

H1 2017

 

H1 2016

H1 2017

 

H1 2016

H1 2017

 

H1 2016

H1 2017

 

 

€ million

€ million

 

€ million

€ million

 

€ million

€ million

 

€ million

€ million

 

€ million

€ million

1

For definition see Annual Report 2016, Chapter “Alternative Performance Measures Used by the Bayer Group.”

2

Full-time equivalents

Net sales (external)

 

506

504

 

2

7

 

17,862

18,394

 

5,825

7,043

 

23,687

25,437

Change1

 

−6.5%

−0.4%

 

 

+1.5%

+3.0%

 

−6.0%

+20.9%

 

−0.5%

+7.4%

Currency-adjusted change1

 

−5.9%

+0.6%

 

 

+5.3%

+1.2%

 

−4.3%

+19.6%

 

+2.8%

+5.7%

Intersegment sales

 

903

1,218

 

(980)

(1,307)

 

 

39

41

 

Net sales (total)

 

1,409

1,722

 

(978)

(1,300)

 

 

5,864

7,084

 

23,687

25,437

EBIT1

 

21

19

 

(59)

(243)

 

3,755

3,890

 

703

1,377

 

4,458

5,267

EBIT before special items1

 

46

50

 

(48)

(240)

 

4,131

4,236

 

703

1,321

 

4,834

5,557

EBITDA before special items1

 

141

163

 

(45)

(234)

 

5,394

5,301

 

1,047

1,648

 

6,441

6,949

Net cash provided by operating activities

 

167

(241)

 

(33)

73

 

2,066

2,452

 

478

690

 

2,544

3,142

Depreciation, amortization, impairment losses / loss reversals

 

95

113

 

3

6

 

1,509

1,244

 

344

318

 

1,853

1,562

Number of employees (as of June 30)2

 

19,114

24,640

 

752

593

 

99,846

99,720

 

15,730

15,960

 

115,576

115,680